CTSB and leishmaniasis: Cathepsin B has already been proposed as a therapeutic target for inflammatory diseases, and for leishmaniasis, and our work brings forth new evidence on the effects that cathepsin B inhibition might have at the T cell level, and sets the stage for future investigation.